

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-158 (canceled)

Claim 159 (new): A pharmaceutically acceptable, solution formulation comprising human FSH and a preservative in an aqueous diluent, wherein

- (a) the preservative is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, thimerosal, and mixtures thereof,
- (b) the concentration of FSH is 5.0 µg/mL to 2 mg/mL,
- (c) the FSH consists of an  $\alpha$ -subunit having SEQ ID NO:5 and a  $\beta$ -subunit having SEQ ID NO:6, held together by noncovalent interactions, and
- (d) the formulation is suitable for multi-dose administration by injection.

Claim 160 (new): A pharmaceutically acceptable, solution formulation comprising an FSH variant and a preservative in an aqueous diluent, wherein

- (a) the preservative is selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, thimerosal, and mixtures thereof,
- (b) the concentration of FSH is 5.0 µg/mL to 2 mg/mL,
- (c) the FSH variant consists of an  $\alpha$ -subunit having SEQ ID NO:5 and a  $\beta$ -subunit having SEQ ID NO:11, held together by noncovalent interactions, and
- (d) the formulation is suitable for multi-dose administration by injection.